Drug Trial Radar · NCT06463665
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
142
Planned (sponsor's estimate)
Start
Sep 26, 2024
Primary completion
Feb 2027
Study completion Jul 2029
Sponsor
- Lead sponsor
- Genelux CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- Newsoara Biopharma Co., Ltd.
- First posted
- Jun 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. docetaxel for patients with advanced or metastatic NSCLC who have shown first disease progression (i.e., progressive disease not yet confirmed by further scan after initial scan showing progression) while on front-line treatment or maintenance ICI therapy after front-line treatment with platinum-doublet chemotherapy + ICI as standard of care.
Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer
- Advanced Squamous Non-Small Cell Lung Carcinoma
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Metastatic Squamous Non-Small Cell Lung Carcinoma
- Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer Stage III
- Non-small Cell Lung Cancer Stage IV
- Non-small Cell Lung Cancer Recurrent
Interventions
Olvimulogene nanivacirepvecBiological
Olvi-Vec is an engineered oncolytic vaccinia virus
Platinum chemotherapy: carboplatin or cisplatinDrug
Administered according to local practice.
Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLCDrug
Administered according to local practice.
Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumabDrug
Administered according to local practice.
DocetaxelDrug
Administered according to local practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Blinded Independent Central Review (BICR)Time frame: From date of randomization up to 12 months.
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Pioneer Research Center, LLC
Bullhead City, Arizona · Recruiting
Clermont Oncology Center
Clermont, Florida · Recruiting
Oncology & Hematology Associates of West Broward
Coral Springs, Florida · Recruiting
Helios Clinical Research
Fort Lauderdale, Florida · Recruiting
Bioresearch Partner
Hialeah, Florida · Recruiting
University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
Bioresearch Partner
Miami, Florida · Recruiting
Mid Florida Hematology and Oncology Center
Orange City, Florida · Recruiting
BRCR Medical Center, Inc.
Plantation, Florida · Recruiting
Michigan Hematology and Oncology Consultants
Dearborn, Michigan · Recruiting
Oakland Medical Group
Farmington Hills, Michigan · Recruiting
Inspira Medical Center Mullica Hill
Mullica Hill, New Jersey · Recruiting
Gabrail Cancer and Research Center
Canton, Ohio · Recruiting
Texas Oncology - Austin Central
Austin, Texas · Recruiting
World Research Link
Baytown, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.